Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Finished Goods: 2023-2025

  • China SXT Pharmaceuticals' Finished Goods fell 18.97% to $448,668 in Q1 2025 from the same period last year, while for Mar 2025 it was $448,668, marking a year-over-year decrease of 18.97%. This contributed to the annual value of $448,668 for FY2025, which is 18.97% down from last year.
  • China SXT Pharmaceuticals' Finished Goods amounted to $448,668 in Q1 2025, which was down 18.97% from $553,682 recorded in Q1 2024.
  • China SXT Pharmaceuticals' Finished Goods' 5-year high stood at $553,682 during Q1 2024, with a 5-year trough of $446,866 in Q1 2023.
  • Its 3-year average for Finished Goods is $483,072, with a median of $448,668 in 2025.
  • Its Finished Goods has fluctuated over the past 5 years, first rose by 23.90% in 2024, then declined by 18.97% in 2025.
  • Over the past 3 years, China SXT Pharmaceuticals' Finished Goods (Quarterly) stood at $446,866 in 2023, then rose by 23.90% to $553,682 in 2024, then declined by 18.97% to $448,668 in 2025.
  • Its last three reported values are $448,668 in Q1 2025, $553,682 for Q1 2024, and $446,866 during Q1 2023.